I-Mab Forms Discovery Partnerships with mRNA and AI Companies
publication date: Jul 9, 2021
Shanghai I-Mab announced two partnerships to develop oncology candidates with China biopharmas that offer novel discovery technologies. The company will work to develop new therapeutics with Immorna, a Hangzhou mRNA biotech company, and neoX Biotech, a Beijing AI-based R&D biotech. I-Mab will use Immorna's self-replicating mRNA platform, and it will identify up to 10 novel biologic candidates based on neoX's proprietary AI algorithm. Earlier this year , I-Mab announced collaborations with Complix for cell-penetrating antibodies and Affinity for masking antibodies. More details....
Stock Symbol: (NSDQ: IMAB)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.